Strategy & Advisory
When important healthcare decisions call for experience, independent judgment and a clear way forward.

For management teams
I support management teams on important decisions around growth, technology and healthcare – with experience, independent judgment and a clear view of what is practically achievable.
A major technology or AI investment is on the table. Does it make strategic and economic sense?
Vendors, implementation partners and internal stakeholders see an investment from different perspectives. I do not sell software and I do not implement systems. I assess the business case, architecture, dependencies, risks and alternatives.
Outcome: An independent recommendation: invest, adjust, pilot or do not invest.
Sales are not growing as fast as the market.
I analyze pipeline, pricing, partners and key accounts, in conversation with sales and customers, and identify what is actually holding growth back and which levers work in the short term.
Outcome: Five to ten prioritized levers and a 90-day plan with clear owners.
You want to enter the German or DACH market.
I know the German healthcare market from the vendor, operator and investor side. We clarify segment, pricing model and partners before you invest.
Outcome: Market strategy, prioritized partners, pricing approach and a realistic entry plan.
Digitalization and AI should work in everyday operations, not only in a pilot.
I guide the path from pilot to governed operations: priorities, accountability and governance.
Outcome: A roadmap that management and boards can stand behind.
For investors
I support investors before and after a transaction with an independent assessment of the healthcare market, business model, technology and operational value creation – and with translating it into concrete decisions and actions.
Before a transaction: does the investment thesis hold?
I complement classic due diligence workstreams with an experienced healthcare perspective – on the buy side and sell side, particularly in healthcare, health IT and MedTech.
Outcome: A short, IC-ready paper: what holds up, where I see doubts and what you should still verify before signing.
After closing: many initiatives, no clear priorities.
Together with management and the board, I translate the investment thesis into concrete levers, owners, KPIs and a robust timeline.
Outcome: A prioritized 100-day plan and an EBITDA bridge that everyone in the room can follow.
Revenue, pipeline or EBITDA are behind the investment case.
I review the sales engine, revenue quality, pricing and partner ecosystem and identify the few changes that actually move revenue and EBITDA.
Outcome: Five to ten prioritized levers and a 90-day acceleration plan.
Which AI investments really create enterprise value – rather than just more technology?
I prioritize AI use cases by economic impact, feasibility, risk and time to value, and I review planned investments in ERP, platforms and AI.
Outcome: A prioritized portfolio of AI initiatives with business cases and a clear sequence.
The exit is approaching. Is the company ready for its next equity story?
I assess which operational, commercial and technology gaps still limit equity value – and which of them can realistically be closed in the time remaining.
Outcome: A prioritized list of gaps to close before the exit.
I discuss concrete cases and references in confidence.
Healthcare from different perspectives
Experience across healthcare delivery, technology, pharma, MedTech, payers, the public sector and investment — connected by more than two decades of leadership, transformation and advisory work.
Selected organizations I have worked with
In executive roles, advisory engagements and transformation projects.
Providers
Executive role




Executive rolePayers




MedTech



Pharma



Technology
Executive role
Public & Nonprofit
Investors & Private Equity
* Executive role (not a consulting engagement).
Independent. Confidential. Clear in scope.
- No software sales, no implementation or commission interests. I disclose my former SAP role.
- I name potential conflicts of interest upfront.
- Scope and fixed fee are agreed before the start.
- Confidential and NDA-ready.
How we start
- 30 minutes: understand the situation and the decision
- Usually within 48 hours: scope, outcome, fee and possible start date
- Start: by agreement
- Outcome: a clear recommendation and a prioritized action plan
Depending on the situation, I work on a single decision or, over a defined period, as a sounding board for management or investors.
For supervisory and advisory board mandates: Executive & Board →
When an important decision is coming up
If you are facing an important growth, investment or technology decision, we can clarify in 30 minutes whether and how I can usefully help.